LRP6 and sarcoma: Consistent with these reports, treatment of a Wnt autocrine human sarcoma cell line, U2-OS [30], with Nystatin increased cell surface LRP6 levels and simultaneously decreased uncomplexed β-catenin levels (Figure 3A).